Physician profile
William A Bergin
NPI 1427284439
$1,563.84
in general payments reported to CMS, 2019-2025
26 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $101 · 2021: $87.53 · 2022: $351 · 2023: $365 · 2024: $200 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $338.45 | 2021-2025 | Qulipta, Ubrelvy |
| Abbott Laboratories | $205.39 | 2022-2023 | Proclaim, Infinity |
| Pfizer INC. | $167.07 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $127.72 | 2019-2025 | Dysport |
| Amgen INC. | $81.86 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $67.05 | 2024-2025 | Xeomin |
| Lundbeck LLC | $64.81 | 2021-2022 | |
| Pacira Therapeutics, INC. | $48.11 | 2019 | |
| Averitas Pharma INC. | $47.26 | 2024 | Qutenza |
| Novartis Pharmaceuticals Corporation | $47.16 | 2020-2021 | |
| Lilly USA, LLC | $38.27 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $38.11 | 2023 | Relyvrio |
| Xeris Pharmaceuticals, INC. | $36.77 | 2023-2025 | Keveyis |
| Amneal Pharmaceuticals LLC | $36.30 | 2019-2020 | |
| Medtronic, INC. | $33.71 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $26.68 | 2024 | Nuedexta |
| Electronic Waveform Lab, INC. | $25.64 | 2022 | |
| Allergan, INC. | $20.30 | 2019 | |
| Penumbra, INC. | $20.00 | 2020 | |
| Scilex Pharmaceuticals INC. | $16.71 | 2019 | |
| Virtus Pharmaceuticals LLC | $15.56 | 2025 | Levorphanol Tartrate |
| Biogen, INC. | $14.21 | 2019 | |
| Boston Scientific Corporation | $14.08 | 2024 | |
| Upsher-Smith Laboratories LLC | $12.80 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.79 | 2022 | |
| Si-Bone, INC. | $8.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bergin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.